
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. reported a significant 41% quarter-over-quarter increase in NeXT Personal Dx volumes in Q4'25, surpassing prior expectations and indicating robust demand for its genomic sequencing and analytics solutions. The recent announcement of Medicare coverage and pricing for the NeXT Personal MRD test, particularly for breast cancer, has further bolstered investor confidence, contributing to a 28% increase in share value. Additionally, the anticipated acceleration of marketing efforts by commercial partner Tempus is expected to drive even higher volumes and revenue growth moving forward.
Bears say
Personalis Inc's outlook is negatively impacted by a lower revenue guidance for Q4 2025, attributed to a general slowdown in the biopharma sector and logistical challenges with global sample handling. Additionally, the company has faced a year-over-year decline in revenue from its pharmaceutical services, significantly influenced by the conclusion of enrollment in Moderna's Phase III melanoma trial. Despite raising $109 million from an ATM facility, concerns regarding ongoing losses, debt on the balance sheet, and the risk of being unable to achieve long-term profitability further contribute to the unfavorable sentiment surrounding Personalis's financial health.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares